

Weekly

August 23, 2002 / Vol. 51 / No. 33

Unrecognized HIV Infection, Risk Behaviors, and Perceptions of Risk Among Young Black Men Who Have Sex with Men — Six U.S. Cities, 1994–1998

The incidence of human immunodeficiency virus (HIV) infection among young black men who have sex with men (BMSM) is among the highest of all risk groups in the United States (1-3). Two important strategies to reduce HIV transmission among young BMSM are to increase the proportion of men who are aware of their HIV infection and to increase the consistent use of condoms among sexually active men (4,5). However, limited information is available to help develop HIV-testing and condom-promotion programs for young BMSM. To address this need, data from CDC's Young Men's Survey (YMS) were used to evaluate the prevalence of unrecognized HIV infection, barriers to testing, and reasons for nonuse of condoms among BMSM aged 15-22 years. This report summarizes the results of the survey, which indicated that of the 16% of young BMSM participants who were infected with HIV, nearly all were unaware of their infection. Few young BMSM reported testing frequently for HIV, and many reported engaging in behaviors that could transmit HIV because they perceived themselves or their partners to be at low risk for infection. These findings underscore the urgency of expanding and improving prevention efforts for young BMSM by increasing the demand for and availability of HIV-testing services and by providing high-quality prevention counseling that includes assessment and clarification of perceived risks for infection.

YMS was a cross-sectional survey conducted during 1994– 1998 of males aged 15–22 years who attended MSMidentified venues (e.g., shopping areas, dance clubs, bars, and organizations) in Baltimore, Maryland; Dallas, Texas; Los Angeles, California; Miami, Florida; New York, New York; the San Francisco Bay Area, California; and Seattle, Washington (1). Extensive formative research was conducted to construct monthly sampling frames of the days, times, and venues attended by young BMSM. Each month, 12–16 venues and their associated day/time periods were selected randomly and scheduled for sampling. During sampling events, men were approached consecutively to assess their survey eligibility. BMSM eligible for the survey were aged 15–22 years and residents in one or more local counties. Participants were interviewed by using a standard questionnaire, had blood drawn for HIV testing, were given appointments to obtain test results, and were provided HIV-prevention counseling and referral for care when needed.

Specimens were tested for HIV at local laboratories with standard assays. Analyses were restricted to men who reported ever having sex with men and who described their racial background as either being only black or having a mixed background that included being black. Analyses excluded records of duplicate participants, who were identified by using the Miragen antibody profile assay (6). Records also were excluded from Seattle because few BMSM had participated in that city.

In the six cities, 920 BMSM participated in YMS (range: 127–202). The participation rate among eligible blacks was 61% (range: 53%–77%). Of the 920 participants, 150 (16%) tested positive for HIV (range: 13%–18%). Of the 150 HIV-infected BMSM, 139 (93%) were unaware of their infection (range: 88%–100%). Of those with unrecognized infection,

INSIDE

- 736 Nonfatal Sports- and Recreation-Related Injuries Treated in Emergency Departments — United States, July 2000–June 2001
- 740 Delayed Diagnosis of Fragile X Syndrome United States, 1990–1999
- 742 West Nile Virus Activity United States, August 15–21, 2002

CENTERS FOR DISEASE CONTROL AND PREVENTION SAFER • HEALTHIER • PEOPLE[™] The *MMWR* series of publications is published by the Epidemiology Program Office, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

SUGGESTED CITATION

Centers for Disease Control and Prevention. [Article Title]. MMWR 2002;51:[inclusive page numbers].

Centers for Disease Control and Prevention

Julie L. Gerberding, M.D., M.P.H. Director

David W. Fleming, M.D. Deputy Director for Science and Public Health

Dixie E. Snider, Jr., M.D., M.P.H. Associate Director for Science

Epidemiology Program Office

Stephen B. Thacker, M.D., M.Sc. Director

Office of Scientific and Health Communications

John W. Ward, M.D. Director Editor, MMWR Series

David C. Johnson Acting Managing Editor, MMWR (Weekly)

> Jude C. Rutledge Teresa F. Rutledge Jeffrey D. Sokolow, M.A. *Writers/Editors,* MMWR (*Weekly*)

Lynda G. Cupell Malbea A. Heilman Beverly J. Holland Visual Information Specialists

Quang M. Doan Erica R. Shaver Information Technology Specialists

Division of Public Health Surveillance and Informatics

Notifiable Disease Morbidity and 122 Cities Mortality Data Robert F. Fagan Deborah A. Adams Felicia J. Connor Lateka Dammond Patsy A. Hall Pearl C. Sharp 99 (71%) reported either that there was no chance, that it was very unlikely, or that it was unlikely that they were infected with HIV; 58 (42%) perceived themselves at low risk for ever becoming infected; and 45 (32%) perceived themselves at low risk both for being and for ever becoming HIV-infected (Table).

During the 6 months preceding the survey, the 920 BMSM reported a median of two male sex partners (interquartile range: one to three), 712 (77%) reported having anal intercourse with another man, and 342 (37%) reported having unprotected anal intercourse (UAI). Of the 79 BMSM with unrecognized HIV infection who had UAI, 41 (52%) reported not using condoms for one or more of the following reasons: they "knew" they were HIV-negative (24%), they "knew" their partners were HIV-negative (20%), or they thought their partners were at low risk for infection (35%); 34 (43%) also reported not using condoms because none were available (Table).

Of the 920 BMSM, 585 (64%) had ever tested previously for HIV, but few had tested frequently (median number of tests: one; interquartile range: zero to two). Of those who had tested previously, 536 (92%) reported last testing HIVnegative, and of these, 87 (16%) were found to be infected with HIV. The 332 (36%) men who had not tested previously gave the following reasons for not testing (more than one reason could be given): low risk for infection (45%), fear of learning their results (41%), and fear of needles (21%). Of those who had not tested previously, 42 (13%) were HIVinfected. Of the 148 men who had not tested previously because of perceived low risk, 122 (82%) ever had anal intercourse with a man, 99 (67%) had at least three lifetime male partners, and 11 (7%) were HIV-infected.

Compared with their noninfected peers, young BMSM with unrecognized infection were more likely to report engaging in UAI and not testing previously because of fear about learning their results (Table). Noninfected young BMSM were more likely to perceive themselves at low risk for infection and not to have tested previously because of this perception.

Reported by: T Bingham, MPH, Los Angeles County Dept of Health Svcs, Los Angeles; W McFarland, MD, San Francisco Dept of Public Health, San Francisco, California. DA Shehan, Univ of Texas Southwestern Medical Center at Dallas, Texas. M LaLota, MPH, Florida Dept of Health. DD Celentano, ScD, Johns Hopkins Univ School of Hygiene and Public Health, Baltimore, Maryland. BA Koblin, PhD, New York Blood Center; LV Torian, PhD, New York City Dept of Health, New York. DA MacKellar, MPH, LA Valleroy, PhD, GS Secura, MPH, RS Janssen, MD, Div of HIV/AIDS Prevention–Surveillance, and Epidemiology; GW Roberts, PhD, Div of HIV/AIDS Prevention– Intervention, Research, and Support, National Center for HIV, STD, and TB Prevention, CDC.

TABLE. Percentage of black men aged 15–22 years who have sex with men who reported low perceived risk for human immunode
ficiency virus (HIV) infection, previous HIV testing, and sexual risk behavior, by HIV status - six cities*, United States, 1994–1998

	Infected unaware [†] (n=139)	Noninfected (n=770)	
Characteristic	%	%	p value§
Low perceived risk			
Being HIV-infected [¶]	71	86	<0.01
Becoming HIV-infected**	42	51	0.06
Being/becoming HIV-infected ^{††}	32	47	<0.01
Previous HIV tests			
Ever	70	62	0.07
Last test negative ^{§§}	63	58	0.34
Last test unknown or indeterminate	7	4	0.06
Last negative test <1 year before interview	41	41	0.88
≥3 tests	28	21	0.08
Reasons for not testing previously			
(Of nontested men; n=332)	(n=42)	(n=290)	
Perceived low risk for infection	26	47	< 0.01
Scared to learn results	55	39	0.04
Scared of needles	17	22	0.69
Sexual risk behavior ^{¶¶}			
≥3 partners	41	37	0.40
Anal intercourse, insertive or receptive	91	75	<0.01
Unprotected anal intercourse (UAI)***	57	34	<0.01
Reasons for nonuse of condoms ^{†††}			
(Of men who had UAI: n=338)	(n=79)	(n=259)	
Participant "knew" he was HIV-negative	24	33	0.11
Participant "knew" his partner was HIV-negative	20	33	0.02
Participant thought his partner was at low risk for HIV	35	36	0.81
Condom was not available	43	37	0.42
Participant was under the influence of alcohol or drugs	27	16	0.06
Participant did not think about it or was too emotionally involved	16	16	0.90
Partner did not like using condoms	23	20	0.69
Participant did not like using condoms	15	14	0.81

* Baltimore, Maryland; Dallas, Texas; Los Angeles, California; Miami, Florida; New York, New York; and the San Francisco Bay Area, California.

⁺ Study participants who tested HIV-positive and who reported not ever testing HIV-positive previously.

S Cochran-Mantel-Haenszel chi-square comparing infected unaware with noninfected, controlling for city.

¹ Measured by respondent answering "no chance of it," "very unlikely," or "unlikely" to the following question: "Which of the following describes how likely it is that you are infected with HIV today?"

** Measured by respondent agreeing with the following statement: "There is little chance that I could become infected with HIV, or infect others, from what I do sexually."

Perceived low risk for both being HIV-infected and ever becoming infected.

Nost recent HIV test before study participation.

¹¹ With other men only during the 6-month period preceding the survey.

*** Measured as not always using condoms during insertive or receptive anal intercourse.

⁺⁺⁺ More than one reason could be given.

Editorial Note: The findings in this report are consistent with previous studies suggesting that in several U.S. cities, the majority of young HIV-infected MSM, particularly BMSM, were unaware of their infection (1,7). In a preliminary analysis of 573 HIV-infected MSM aged 16–29 years sampled in six U.S. cities, proportionally more BMSM were unaware of their infection than were white MSM (91% versus 60%) (7). However, among all young MSM with unrecognized HIV infection, no racial or ethnic differences were observed among those perceiving themselves at low risk for being infected (66%), engaging in UAI (54%), or not using condoms during anal intercourse because of perceived low personal or

partner risks for HIV infection (46%) (7). These findings underscore the urgency of improving HIV-prevention efforts for all young MSM by 1) increasing the demand for and availability of HIV-testing services and 2) providing young MSM with high-quality HIV- and STD-prevention services that include assessment and clarification of personal risks for infection.

In accordance with recently revised guidelines, health-care providers should assess the HIV risks of their patients routinely and encourage all MSM at risk for HIV to test at least annually (8,9). Findings from this report indicate that demand for testing by young BMSM might be increased by implementing efforts that increase personal risk perceptions; addressing concerns about testing positive by conveying the benefits of early diagnosis and HIV care; and marketing the availability of oral fluid, urine-based, or finger-stick HIV tests that do not require venipuncture (9). Use of testing services also might be increased by offering testing in nonclinical settings that serve or are attended by young BMSM and by providing high-quality partner referral services for all those who test positive (5,9).

HIV testing should be accompanied by high-quality prevention counseling that includes an in-depth personalized risk assessment, clarification of risk perceptions, and negotiation of steps to reduce risks (9). Because 16% of young BMSM who reported being HIV-negative were found to be HIV-infected, providers should encourage young BMSM to use condoms consistently with all partners, including those who have tested negative previously. In negotiating risk reduction with young BMSM, providers should be prepared to address alcohol, drug, and partner influences on condom use and to help young BMSM cope with emotional responses in high-risk situations. Providers should refer clients who have difficulty in initiating or sustaining safer behavior for more intensive individualized prevention counseling and support services (9,10). Finally, managers of prevention programs should consider increasing the availability of condoms in settings where young BMSM are likely to encounter sex partners.

The findings in this report are subject to at least three limitations. First, findings might not be applicable to young BMSM who do not attend MSM-identified venues or reside in the six participating cities. Second, because approximately 39% of eligible young BMSM chose not to participate, selective nonparticipation could have biased reported findings. Finally, data were collected during face-to-face interviews and are subject to disclosure biases. The finding that nearly all HIV-infected young BMSM in this survey were unaware of their infection might be attributed, in part, to one or more of these biases. However, a high proportion of young BMSM who are unaware of their infection is likely given the high HIV incidence and low frequency of testing among young BMSM (2).

In partnership with state and local health departments, nongovernment organizations, community stakeholders, and other federal agencies, CDC is taking steps to reduce HIV transmission and unrecognized infection among young MSM, particularly BMSM. Since September 2001, five national consultations have helped identify current prevention needs of MSM, including young minority MSM. In 2001, additional resources were made available to expand HIV counseling and testing, outreach services, and behavioral risk-reduction interventions for young minority MSM. Ongoing prevention efforts also are being strengthened through capacity development for minority community-based organizations serving young MSM, and through recently released guidelines calling for expanded risk assessment and HIV testing for homosexual and bisexual men (8,9). Finally, new research efforts, including rapid ethnographic assessments, have been initiated to identify additional factors that influence HIV-acquisition risks among young minority MSM. These and similar efforts signal the increased priority at national, state, and local levels to reduce the considerable racial disparities in HIV morbidity and unrecognized infection among young MSM.

References

- 1. Valleroy LA, MacKellar DA, Karon JM, et al. HIV prevalence and associated risks in young men who have sex with men. JAMA 2000;284:198–204.
- CDC. HIV incidence among young men who have sex with menseven U.S. cities, 1994–2000. MMWR 2001;50:440–4.
- 3. Karon JM, Fleming PL, Steketee RW, De Cock KM. HIV in the United States at the turn of the century: an epidemic in transition. Am J Public Health 2001;91:1060–8.
- 4. CDC. HIV prevention strategic plan through 2005. Atlanta, Georgia: U.S. Department of Health and Human Services, CDC, 2001.
- Janssen RS, Holtgrave DR, Valdiserri RO, Shepherd M, Gayle HD, De Cock KM. The serostatus approach to fighting the HIV epidemic: prevention strategies for infected individuals. Am J Public Health 2001;91:1019–24.
- 6. Unger TF, Strauss A. Individual-specific antibody profiles as a means of newborn infant identification. J Perinatol 1995;15:152–4.
- MacKellar D, Valleroy L, Secura G, et al. Unrecognized HIV infection, risk behavior, and mis-perception of risk among young men who have sex with men—6 U.S. cities, 1994–2000 [Abstract]. Barcelona, Spain: 14th International AIDS Conference, July 2002.
- CDC. Sexually transmitted diseases treatment guidelines 2002. MMWR 2002;51(no. RR-6):7–10.
- CDC. Revised guidelines for HIV counseling, testing, and referral, and revised recommendations for HIV screening of pregnant women. MMWR 2001;50(no. RR-19).
- CDC. HIV prevention case management, literature review and current practice. Atlanta, Georgia: U.S. Department and Health and Human Services, CDC, 1997:1–30.

Nonfatal Sports- and Recreation-Related Injuries Treated in Emergency Departments — United States, July 2000–June 2001

Each year in the United States, an estimated 30 million children and adolescents participate in organized sports (1), and approximately 150 million adults participate in some type of nonwork-related physical activity (2). Engaging in these activities has numerous health benefits but involves a risk for injury. CDC analyzed data from the National Electronic Injury Surveillance System All Injury Program (NEISS-AIP) to characterize sports- and recreation-related injuries among the U.S. population. This report summarizes the results of that analysis, which indicate that during July 2000–June 2001 an estimated 4.3 million nonfatal sports- and recreation-related injuries were treated in U.S. hospital emergency departments (EDs). Injury rates varied by sex and age and were highest for boys aged 10–14 years. Effective prevention strategies, including those tailored to specific activities and those aimed at children, adolescents, and adults, are needed to reduce sports- and recreation-related injuries in the United States.

NEISS-AIP is operated by the U.S. Consumer Product Safety Commission (CPSC) and collects data on initial visits for all types and causes of injuries treated in U.S. EDs. NEISS-AIP data are drawn from a nationally representative subsample of 66 out of 100 NEISS hospitals, which were selected as a stratified probability sample of hospitals in the United States and its territories with a minimum of six beds and a 24-hour ED. NEISS-AIP provides data on approximately 500,000 injury- and consumer product–related ED cases each year.

Sports- and recreation-related injuries included those occurring during organized and unorganized activities, whether work-related or not. An injury was defined as bodily harm resulting from exposure to an external force or substance. Each case was classified into one of 39 mutually exclusive sports- and recreation-related groups based on an algorithm that considered both the consumer products involved (e.g., bicycles or accessories, swings or swing sets, or in-line skating [activity, apparel, or equipment]) and the narrative description of the incident. Cases were excluded if 1) the principal diagnosis was an illness, pain only, psychological harm only, contact dermatitis associated with consumer products or plants, or unknown; 2) the ED visit resulted from the adverse effects of therapeutic drugs or surgical care; or 3) the injury was violence-related, including intentional self-harm, assault, or legal intervention. Because deaths are not captured completely by NEISS-AIP, persons who were dead on arrival or who died in the ED also were excluded.

Each case was assigned a sample weight based on the inverse probability of selection; these weights were added to provide national estimates of sports- and recreation-related injuries. Estimates were based on weighted data for 70,060 sports- and recreation-related ED visits during July 2000–June 2001. Confidence intervals (CIs) were calculated by using a direct variance estimation procedure that accounted for the sample weights and complex sample design. Rates were calculated by using averaged 2000–2001 U.S. Census Bureau population data.

During July 2000–June 2001, an estimated 4.3 million (95% CI=3.7–4.8 million) sports- and recreation-related injuries were treated in U.S. hospital EDs, comprising 16%

of all unintentional injury-related ED visits (Table 1). The percentage of all unintentional injury-related ED visits that were sports- and recreation-related was highest for persons aged 10–14 years (51.5% for boys, 38.0% for girls), and lowest for persons aged \geq 45 years (6.4% for men, 3.1% for women). The overall rate of sports- and recreation-related injuries was 15.4 per 1,000 population (Table 1). Rates were highest among persons aged 10–14 years (75.4 for boys, 36.3 for girls), and lowest among persons aged 0–4 years (11.1 for boys, 6.8 for girls) and persons aged \geq 45 years (4.3 for men, 2.2 for women). Among all ages, rates were higher for males than for females (Figure).

Types of sports- and recreation-related activities in which persons were engaged when injured varied by age and sex. For persons aged 0-9 years, the leading types were playgroundand bicycle-related injuries (Table 2). Both scooter- and trampoline-related injuries ranked among the top seven types of injuries for both boys and girls aged 0-9 years. For males aged 10-19 years, football-, basketball-, and bicycle-related injuries were most common. For females aged 10-19 years, basketball-related injuries ranked highest. For persons aged 20-24 years, basketball- and bicycle-related injuries ranked among the three leading types of injuries. Basketball-related injuries ranked highest for men aged 25-44 years. Exercise (e.g., weight lifting, aerobics, stretching, walking, jogging, and running) was the leading injury-related activity for women aged ≥ 20 years and ranked among the top four types of injuries for men aged ≥ 20 years.

The most frequent injury diagnoses were strains/sprains (29.1%; 95% CI=25.2%–33.0%), fractures (20.5%; 95% CI=16.5%–24.5%), contusions/abrasions (20.1%; 95% CI=17.5%–22.8%), and lacerations (13.8%; 95% CI=11.9%–15.8%). The body parts injured most commonly were ankles (12.1%; 95% CI=10.9%–13.4%), fingers (9.5%; 95% CI=8.2%–10.8%), face (9.2%; 95% CI=7.9%–10.5%), head (8.2%; 95% CI=6.4%–10.1%), and knees (8.1%; 95% CI=6.8%–9.4%). Of an estimated 350,734 (95% CI=270,417–431,051) persons with sports- and recreation-related head injuries, approximately 199,050 (95% CI=127,947–270,153) had a brain injury diagnosed (i.e., diagnosis of concussion or internal injury). Overall, 2.3% (95% CI=1.5%–3.0%) of persons with sports- and recreation-related injuries were hospitalized.

Reported by: K Gotsch, JL Annest, PhD, P Holmgreen, MS, Office of Statistics and Programming; J Gilchrist, MD, Div of Unintentional Injury Prevention, National Center for Injury Prevention and Control, CDC.

Editorial Note: This report indicates that an estimated 4.3 million sports- and recreation-related injuries are treated each year in U.S. EDs. These injuries occur among all population

lale 0- 4 5- 9 10-14 15-19 20-24 25-44 ≥45 Unknown All ages emale 0- 4 5- 9 10-14 15-19	All nonfa	atal uninte	ntional injuries	Nonfatal unintentional sports- and recreation-relate				
Sex and age (yrs)	No.	Rate	(95% Cl [§])	No.	Rate	(95% CI)	%	(95% CI)
Male								
0-4	1,350,795	140.0	(113.5–166.6)	107,019	11.1	(9.2–13.0)	7.9	(7.2-8.6)
5- 9	1,203,060	119.6	(100.3–138.9)	366,102	36.4	(32.0-40.8)	30.4	(27.2-33.7)
10–14	1,506,104	146.4	(126.6-166.2)	775,938	75.4	(65.2-85.7)	51.5	(48.1–55.0)
15–19	1,690,177	164.6	(144.3-184.8)	650,430	63.3	(54.5-72.2)	38.5	(36.6-40.4)
20–24	1,573,437	164.6	(138.0-191.2)	292,743	30.6	(24.5-36.8)	18.6	(16.9-20.4)
25–44	4,771,763	117.3	(105.0-129.5)	596,063	14.6	(12.2-17.1)	12.5	(10.8 - 14.2)
<u>≥</u> 45	2,962,276	66.3	(59.6-73.1)	190,023	4.3	(2.9-5.6)	6.4	(4.6-8.2)
Unknown	3,773			105				
All ages	15,061,385	111.4	(99.7–123.1)	2,978,423	22.0	(19.1–25.0)	19.8	(18.3–21.3)
Female								
0-4	987,236	106.9	(88.2–125.6)	63,220	6.8	(5.6-8.1)	6.4	(5.7-7.1)
5-9	842,959	87.8	(75.1–100.4)	231,143	24.1	(20.9-27.3)	27.4	(24.6-30.3)
10–14	936,619	95.6	(83.3-107.8)	355,950	36.3	(30.8-41.9)	38.0	(34.5-41.5)
15–19	1,043,606	107.5	(94.8-120.2)	207,660	21.4	(17.7-25.0)	19.9	(17.9-21.9)
20–24	1,003,129	109.0	(93.3-124.6)	77,416	8.4	(5.7–11.1)	7.7	(6.1-9.4)
25–44	3,474,024	84.0	(77.3-90.7)	221,135	5.3	(4.3-6.4)	6.4	(5.3-7.5)
≥45	3,680,452	70.1	(62.2-78.1)	115,518	2.2	(1.4-3.0)	3.1	(2.1-4.1)
Unknown	1,949		. ,	256		. ,		. ,
All ages	11,969,974	84.7	(77.2-92.1)	1,272,299	9.0	(7.6–10.4)	10.6	(9.4–11.8)
Total [¶]	27,038,199	97.8	(88.5–107.1)	4,251,599	15.4	(13.2–17.5)	15.7	(14.4–17.1)

TABLE 1. Number* and rate[†] of nonfatal unintentional injuries and nonfatal unintentional sports- and recreation-related injuries treated in emergency departments, by age group and sex — National Electronic Injury Surveillance System All Injury Program, United States, July 2000–June 2001


* Numbers might not add to totals because of rounding

Per 1,000 persons.

⁸ Confidence interval

¹ Includes persons for whom sex was not recorded.

FIGURE. Rate* of nonfatal unintentional sports- and recreationrelated injuries treated in emergency departments, by age and sex — United States, July 2000–June 2001



* Per 1,000 population.

groups and account for more ED visits annually than injuries involving motor-vehicle occupants (3.5 million).

Effective prevention efforts are needed to reduce the risk for these injuries among all population groups. Interventions to reduce the risk for sports- and recreation-related injuries can be classified into three categories: personal countermeasures (e.g., use of safety gear), behavioral interventions (e.g., proper conditioning), and environmental modifications (e.g., use of padded goal posts). Specific prevention recommendations vary by sport and recreation activity, and some activityspecific interventions can decrease the risk for injury. For example, wearing helmets while bicycling reduces the risk for head injury by 85% (4), and using breakaway bases decreases the number of sliding-related baseball and softball injuries by 96% (5). Further studies are needed to identify effective interventions for other activities and injury types.

Data on sports- and recreation-related injuries from other national and state hospital-based data systems are limited because the *International Classification of Diseases, Ninth Revision, Clinical Modification* external cause-of-injury codes (E codes) typically do not specify the type of activity in which the person was engaged at the time of injury. In comparison, these types of injuries can be classified from NEISS-AIP data by using the consumer product codes and a narrative description of the incident. This approach makes NEISS-AIP a useful surveillance tool for characterizing and monitoring sportsand recreation-related injuries and identifying emerging injury problems requiring further investigation.

Estimates in this report are higher than those found during 1997–1998 by the National Hospital Ambulatory Medical Care Survey, which indicated that an estimated 3.7 million ED visits were made annually to treat sports- and recreation-

MMWR

	0–4 y	rs	5-9	9 yrs	10-14	1 yrs	15–	19 yrs	20-2	24 yrs	25–	44 yrs	<u>≥</u> 45	ōyrs	т	otal
Rank	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)
Males																
1	Playgro	ound	Bio	cycle	Foot	ball	Bas	ketball	Basł	ketball	Bas	ketball	Bic	cycle	Bas	ketball
	32,237 (144,907		168,691				117,861		40,926			2 (17.5)
		,		. ,		. ,		. ,		. ,		. ,		. ,		
2	Bicyc			ground	Bicy			otball		ycle		cycle		rcise [†]		cycle
	24,694 (23.1)	67,883	3 (18.5)	123,764	(16.0)	138,689	9 (21.3)	29,112	(9.9)	77,102	2 (12.9)	21,672	(11.4)	434,37	1 (14.6)
3	Exerc	ise	For	otball	Baske	thall	Bi	cycle	For	otball	Exe	ercise	Fis	hing	For	otball
0	7,784 (117,807			7 (8.1)		(9.0)		5 (8.3)	17,798	-		2 (12.6)
	.,	,	,	(,	,	()	,	(,	,	(,	,	(,	,	(••••)	,	- ()
4	Swimm	•		ooter	Base			occer		rcise		oftball		eback		ercise
	7,292 (6.8)	21,335	5 (5.8)	47,546	(6.1)	30,222	2 (4.6)	17,504	(6.0)	35,604	4 (6.0)	11,020	(5.8)	140,66	1 (4.7)
F	Saaa	tor	Poo	oboll	Skatab	ordina	Com	nbative§	Δ-	T\/1	Fo	othall	Paol	(otholl	Ba	ooboll
5	Scoot 5,455 (seball 2 (5.5)	Skatebo			5 (4.4)		TV [¶] (4.6)		otball 1 (5.9)	10,930	(5 9)		seball 2 (4.6)
	5,455 (5.1)	20,002	- (3.3)	39,271	(3.1)	20,010) (4.4)	10,020	(4.0)	54,514	+ (3.3)	10,330	(5.0)	130,03	2 (4.0)
6	Baset	ball	Bask	ketball	Soc	cer	Ba	seball	So	ccer	A	ATV.	G	olf	Play	ground
	4,771 (4.5)	17,949	9 (4.9)	29,049	(3.7)	26,679	9 (4.1)	11,061	(3.8)	23,488	3 (3.9)	8,469	(4.5)	127,02	8 (4.3)
_	-		-				_									
7	Trampo			poline	Sco			ercise		bative		seball		TV (Q Q)		ccer
	4,539 (4.2)	14,677	7 (4.0)	25,752	(3.3)	24,892	2 (3.8)	10,859	(3.7)	23,115	5 (3.9)	5,760	(3.0)	104,77	5 (3.5)
8	Misc ball g	iames*'	Swin	nming	Playgr	ound	Skate	boarding	So	ftball	Sc	occer	So	ftball	Skatel	boarding
	2,762 (3 (3.4)	20,994			6 (3.6)	10,294			(3.5)		(2.6)		7 (2.8)
						. ,			,	· /		. ,		. ,		. ,
Other ^{††}	17,485 (16.3)	100,740) (27.5)	226,848	(29.2)	156,228	3 (24.0)	88,898	(30.4)	214,042	2 (35.9)	68,522	(36.1)	1,056,39	5 (35.5)
Total	107,019		366,102	2	775,938		650,430)	292,743		596,063	3	190,023		2,978,42	3
F																
Females	Diaurara	u una d	Diave	ground	Baske	thell	Dee	listhall	Биа	ercise	F 14	ercise	Биа	rcise	Di	avala
1	Playgro 25,290 () (25.2)	53,130			ketball 4 (18.1)		(13.2)		5 (13.2)	26,059			cycle 2 (12.8)
	25,290 (40.0)	50,218	(20.2)	55,150	(14.9)	37,072	+(10.1)	10,202	(13.2)	29,200	5 (13.2)	20,059	(22.0)	103,01	2 (12.0)
2	Bicyc	le	Bic	cycle	Bicy	cle	Gymi	nastics§§	Bic	ycle		cycle	Bic	ycle	Bas	ketball
	11,387 (18.0)	52,955	5 (22.9)	38,889	(10.9)	21,865	5 (10.5)	7,429 ^{¶¶}	(9.6)	25,806	6 (11.7)	16,270	(14.1)	114,64	4 (9.0)
	-		-													
3	Trampo			ooter	Soc					(Z O)		seback		eback		ground
	4,016 (6.4)	15,299	9 (6.6)	28,137	(7.9)	19,865	5 (9.6)	6,077	(7.8)	17,743	3 (8.0)	8,380	(7.3)	108,02	3 (8.5)
4	Swimm	ning	Tram	poline	Gymn	astics	Sc	oftball	Gymi	nastics	So	ftball	G	olf	Exe	ercise
	3,818 (•		3 (6.1)	23,183) (8.2)		(6.9)		3 (5.5)	5,050 ^{¶¶}			5 (7.7)
		,		. ,		. ,		. ,		. ,		. ,		. ,		. ,
5	Exerc			nming	Soft			leyball		ftball		ketball		nastics	-	nastics
	3,223 (5.1)	9,723	3 (4.2)	19,886	(5.6)	12,202	2 (5.9)	4,017	(5.2)	9,924	4 (4.5)	4,899	(4.2)	73,40	5 (5.8)
6	Baset	hall	Gym	nastics	Sco	oter	Ev	ercise	Hors	eback	Gym	nastics	Swin	nming	Sc	occer
0	2,193 (2 (3.4)	16,127			2 (5.1)		(3.9)) (4.1)		(3.7)		7 (4.8)
	_,	0.0)	.,	(0)		(. 0,001	- (0)	0,000	(0.0)	0,000	, (,	.,	(0)	,	. (,
7	Scoo			ercise	Playgi			cycle		all games		leyball		wling		ftball
	1,947 ^{¶¶} (3.1)	7,670) (3.3)	16,000	(4.5)	10,275	5 (4.9)	3,016 ^{¶¶}	(3.9)	7,755	5 (3.5)	3,753	(3.2)	56,75	9 (4.5)
0	Cumaa	etion	Othere	katina***	Trome	oline	5-	othall	Curi-	nmina	0,	mmina	Pageres	t oporta ⁺¹	t Ller	seback
8	Gymna 1,380 (kating***) (3.1)	Tramp 13,610			otball I (3.2)	2,826 ^{¶¶}	nming		mming 3 (3.4)		t sports ^{†1} (2.9)		sebаск 6 (3.6)
	1,000 ((ے،ے	7,240	, (0.1)	10,010	(0.0)	0,71	(0.2)	2,020""	(0.7)	7,530	, 0.4)	5,400	(2.3)	-5,55	5 (5.0)
Other ^{††}	9,966 (15.8)	58,202	2 (25.2)	146,988	(41.3)	71,376	6 (34.4)	35,507	(45.9)	101,911	l (46.1)	43,486	(37.6)	551,65	8 (43.4)
Total	63,220	,	231,143	. ,	355,950	. ,	207,660	` '	77,416		221,135	. ,	115,518	. ,	1,272,29	
	00,220		of nonfata	,				-	,		,.00				.,,_0	-

TABLE 2. Number and percentage* of persons with nonfatal unintentional sports- and recreation-related injuries treated in emergency departments, by rank, activity, age group, and sex — National Electronic Injury Surveillance System All Injury Program, United States, July 2000–June 2001

Numbers are national estimates of nonfatal sports- and recreation-related injuries for each sex and age group. Percentages are of the total sports- and recreation-related injuries for each sex and age group. Percentages might not add to 100% because of rounding. Totals for all ages include persons for whom age was not recorded.

Includes weight lifting, aerobics, stretching, walking, jogging, and running. Includes boxing, wrestling, martial arts, and fencing.

§

1 All-terrain vehicle.

Includes lacrosse, tetherball, handball, rugby, other specified ball sports, and unspecified ball sports. Comprises 31 other sports and recreation categories. ** ††

§§

Includes batons, gymnastics, cheerleading, and dancing. ¶¶

Estimates might be unstable because the coefficient of variation is >30%. Includes roller skating and unspecified types of skating; excludes ice and in-line skating. *** †††

Includes badminton, squash, racquet ball, and tennis.

related injuries (6). Although this estimate was based on a review of narrative fields, no consumer product codes were collected, which might have resulted in an underestimation of the number of ED visits. Sports- and recreation-related injuries treated in EDs represent only a portion of these types of injuries that receive medical attention; many more of these injuries are treated in other settings (e.g., health-care providers' offices and clinics) (7).

The findings in this report are subject to at least five limitations. First, injury rates were based on the U.S. population; data on exposure time or frequency of participation were not collected. Because of the lack of exposure data, these estimates cannot be used to compare relative risks for different sports or for different age groups or sexes. Second, NEISS-AIP captures only injuries treated in hospital EDs. Third, it could not be determined whether a sports- and recreation-related injury was a new injury or an aggravation of an injury sustained previously. Fourth, NEISS-AIP narrative descriptions do not provide detailed information about injury circumstances (e.g., whether or not the activity was organized, whether the injury occurred during training or competition, or whether protective equipment was used). Finally, NEISS-AIP is designed to provide national estimates but not state or local estimates.

The national health objectives for 2010 (8) and *The Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity* (9) emphasize the importance of physical activity. The benefits of physical activity are substantial; however, persons engaging in such activity should be aware of their risk for injury. Additional information about safe participation in sports- and recreation-related activities are available at http: //www.cdc.gov/safeusa/siteindex.htm.

Acknowledgments

This report was based on data contributed by T Schroeder, MS, C Downs, A McDonald, MA, and other staff of the Div of Hazard and Injury Data Systems, U.S. Consumer Product Safety Commission; and with the assistance of L Doll, PhD, E Sogolow, PhD, G Ryan, PhD, National Center for Injury Prevention and Control, CDC.

References

- National Institute of Health. Conference on sports injuries in youth: surveillance strategies, 1991. Bethesda, Maryland: National Institute of Health, 1992; NIH publication no. 93-3444.
- 2. CDC. 2000 Behavioral Risk Factor Surveillance System. Available at: http://www.cdc.gov/brfss.
- CDC. National estimates of nonfatal injuries treated in hospital emergency departments—United States, 2000. MMWR 2001;50:340–6.
- Thompson RS, Rivara FP, Thompson DC. A case-control study of the effectiveness of bicycle safety helmets. N Engl J Med 1989;320:1361–7.
- Janda DH, Bir C, Kedroske B. A comparison of standard vs. breakaway bases: an analysis of a preventative intervention for softball and baseball foot and ankle injuries. Foot & Ankle International 2001;22:810–6.

- 6. Burt CW, Overpeck MD. Emergency visits for sports-related injuries. Ann Emerg Med 2001;37:301–8.
- Warner M, Barnes PM, Fingerhut LA. Injury and poisoning episodes and conditions: National Health Interview Survey, 1997. Vital Health Stat 2000;10(202).
- 8. U.S. Department of Health and Human Services. Healthy people 2010, 2nd ed. With understanding and improving health and objectives for improving health (2 vols). Washington, DC: U.S. Department of Health and Human Services, 2000.
- U.S. Department of Health and Human Services. The Surgeon General's call to action to prevent and decrease overweight and obesity. Rockville, Maryland: U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General, 2001.

Delayed Diagnosis of Fragile X Syndrome — United States, 1990–1999


Fragile X syndrome (FXS) is the leading cause of inherited mental retardation, affecting approximately 50,000 persons in the United States (1). FXS occurs when a mutation on the X chromosome is passed from mother to child. Preliminary data suggest that children affected by FXS experience a delay in diagnosis, a pattern common to other single-gene disorders (2). The molecular test used to definitively diagnose FXS became available in 1991. The first indication of FXS within a family is usually the diagnosis of FXS in a child. Although no proven treatments exist for FXS, prompt diagnosis enables children to receive early intervention services and families to receive genetic counseling (3,4). To assess the timing of a diagnosis of FXS in an affected child and genetic counseling for the family, the Frank Porter Graham Child Development Institute (University of North Carolina at Chapel Hill) conducted a survey during August-October 2001 of 140 parents whose first child affected by FXS was born and had the condition diagnosed during 1990–1999. This report summarizes the results of that survey, which indicate that approximately half of the families did not learn the diagnosis for more than a year after first concerns about their child's development or behavior, and half reported having subsequent pregnancies before FXS was diagnosed in their first child. These findings emphasize the importance of increased opportunities for early diagnosis so children and families can receive all possible benefits, including genetic counseling and intervention services.

No population-based registries for FXS exist in the United States, and few children are identified by routine surveillance systems for birth defects and developmental disabilities. To gather an adequate number of families in a short time frame, investigators used a convenience sample from mailing lists of research institutions and parent-based groups. The families surveyed were identified through two sources: the Carolina Fragile X Project, comprising families in the southeastern United States ascertained for a longitudinal cohort study of FXS (2), and the FRAXA Research Foundation, a parent-based group focused on FXS education and research. The questionnaire asked about the process of finding out about the FXS diagnosis and the impact of the diagnosis on the family. Each parent of a child with FXS was asked to complete the questionnaire, with the assurance that answers were confidential and could not be linked to names. Approximately 535 questionnaires were mailed, and 460 questionnaires representing 299 distinct families were completed. If both parents from the same family responded, the mother's questionnaire was chosen for analysis. Nonbiologic parents (n=nine), parents who knew their FXS carrier status before the index pregnancy (n=16), and parents whose children were born before 1990 (n=134) were excluded; 140 families (126 boys) were included in the survey.

At the time the questionnaire was completed, the mean age of the 140 respondents was 37.6 years (standard deviation: 5.8 years); 93% of the respondents were white, 61% had completed at least an undergraduate degree, and 37% had an annual household income >\$100,000. Before becoming pregnant with the first child affected by FXS, 40 (29%) of 139 respondents knew that they had a family history of mental retardation, learning problems, or behavioral problems.

In this sample, all children had FXS diagnosed after birth when symptoms began to develop. After the first contact with a health-care provider, 34 (24%) of 140 respondents reported visiting a health-care provider about the child's development >10 times before the genetic test for FXS was ordered (Figure). Because girls with FXS might have less distinct physical features, historical endpoints were calculated only for boys.

FIGURE. Percentage of children* who had fragile X syndrome diagnosed, by number of visits to a health-care provider about concerns for the child's development and behavior before diagnosis was made — United States, 1990–1999



A substantial gap existed between the child's age at the time someone became concerned about the child's development or behavior (median age: 12 months; range: 0–50 months) and the child's age at diagnosis of FXS (median age: 26 months; range: 6–101 months).

For many parents, the delay between the birth of the child and FXS diagnosis precluded informed reproductive decisions. Of the 140 parents, 70 (50%) reported having another child before their first child had FXS diagnosed; of these 70 parents, 30 (43%) had another child affected by FXS before the first child had FXS diagnosed. Overall, 124 (89%) of 139 parents reported receiving genetic counseling, and 99 (73%) of 136 reported that the diagnosis affected their decision to have another child. When parents were asked to choose the best time to offer voluntary genetic testing for FXS, 103 (75%) of 138 indicated that the best time would be before a woman becomes pregnant.

Reported by: DB Bailey, PhD, D Skinner, PhD, K Sparkman, Frank Porter Graham Child Development Institute, Univ of North Carolina at Chapel Hill. CA Moore, MD, RS Olney, MD, National Center on Birth Defects and Developmental Disabilities; DC Crawford, PhD, EIS Officer, CDC.

Editorial Note: This report documents both the occurrence of a delayed diagnosis for a child with FXS and the impact this delay has on family planning. Early identification provides benefits for both the family and the affected child. First, early identification provides parents with a diagnosis, potentially reducing the psychosocial impact they face in searching for the cause of their child's disorder and providing more impetus for participation in early intervention programs. Second, early identification could provide parents an opportunity to receive genetic counseling for family planning. Third, early identification would allow the child to receive available intervention services. Infants who have FXS diagnosed are immediately eligible for publicly funded developmental services (e.g., early intervention programs) in all 50 states under Part C of the Individuals with Disabilities Education Act (5). Finally, early identification allows researchers to better understand the natural history of the disorder and provides an opportunity for testing the effectiveness of new interventions (5).

Despite the potential benefits of early identification, strategies for obtaining an early diagnosis in a child are limited. Two such strategies are newborn screening (3, 6, 7) and early clinical recognition (8, 9). Adding disorders such as FXS to newborn screening programs would guarantee a timely diagnosis. However, FXS does not have a proven treatment that must be administered shortly after birth, which is the fundamental criterion used to justify rapid, universal identification of a disorder in a newborn (3, 6). Similarly, the clinical screening strategy might not be optimal for early identification of disorders such as FXS. The signs for FXS clinical recognition often are subtle, and no single factor (e.g., severity of mental retardation or behavior) is associated with the variability in the length of time from a child's birth to diagnosis of FXS (5). Strategies to enhance early clinical identification of FXS could include education programs for health-care providers that emphasize the importance of developmental screening and ascertaining family history as part of routine well-child health care, and focusing on improved recognition of the signs and symptoms of FXS and other developmental disorders in young children.

The findings in this report are subject to at least two limitations. First, the convenience sample used for this survey probably does not represent all families affected by FXS in the United States. Respondents were parents who have elected to participate in research in the past or have an active interest in research and policy concerning FXS. Second, because the analyses were limited to a specific time frame, the sample size was relatively small.

Despite these limitations, this survey documents the consequences of a delayed diagnosis of FXS for both the child and the family. Although the strategies to obtain an early diagnosis for disorders such as FXS are limited, new approaches are needed to optimize access to services and information for personal health decisions and family planning.

References

- Crawford DC, Acuña JM, Sherman SL. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med 2001;3:359–71.
- Bailey DB, Skinner DA, Hatton D, Roberts J. Family experiences and factors associated with the diagnosis of fragile X syndrome. J Dev Behav Pediatr 2000;21:315–21.
- Levy HL, Albers S. Genetic screening of newborns. Annu Rev Genomics Hum Genet 2000;1:139–77.
- Barnicoat A. Screening for fragile X syndrome: a model for genetic disorders? BMJ 1997;315:1174–5.
- Bailey DB, Roberts JE, Mirrett P, Hatton DD. Identifying infants and toddlers with fragile X syndrome: issue and recommendations. Infants and Young Children 2001;14:24–33.
- Andrews LB, Fullarton JE, Holtzman NA, Motulsky AG, eds. Assessing genetic risks: implications for health and social policy. Washington, DC: National Academy Press, 1994.
- 7. Clayton EW. What should be the role of public health in newborn screening and prenatal diagnosis? Am J Prev Med 1999;16:111-5.
- American College of Medical Genetics. Fragile X syndrome: diagnostic and carrier testing. Am J Med Genet 1994;53:380–1.
- American Academy of Pediatrics, Committee on Children with Disabilities. Developmental surveillance and screening of infants and young children. Pediatrics 2001;108:192–6.


West Nile Virus Activity — United States, August 15–21, 2002

This report summarizes West Nile virus (WNV) surveillance data reported to CDC through ArboNET and by states and other jurisdictions as of 7:30 a.m. Mountain Daylight Time, August 21, 2002.

During the reporting period of August 15–21, a total of 114 laboratory-positive human cases of WNV-associated illness were reported from Louisiana (n=62), Illinois (n=fourteen), Texas (n=11), Missouri (n=nine), Mississippi (n=seven), Indiana (n=three), Alabama (n=two), Ohio (two), Tennessee (two), Kentucky (n=one), and New York City (n=one). During this period, Kentucky, Missouri, Ohio, Tennessee, and New York City reported their first human cases. During the same period, WNV infections were reported in 458 dead crows, 430 other dead birds, 117 horses, and 318 mosquito pools. During this period, WNV activity was reported for the first time ever in Colorado and Wyoming.

During 2002, a total of 270 human cases with laboratory evidence of recent WNV infection have been reported from Louisiana (n=147), Mississippi (n=55), Texas (n=25), Illinois (n=16), Missouri (n=nine), Alabama (n=five), Indiana (n=four), Ohio (n=two), Tennessee (n=two), the District of Columbia (n=one), Florida (n=one), Kentucky (n=one), Massachusetts (n=one), and New York City (n=one). Thirteen deaths have been reported from Louisiana (n=eight), Mississippi (n=two), Illinois (n=one), Kentucky (n=one), and Texas (n=one) (Figure). Among the patients with available data, the median age was 53 years (range: 3–94 years), and






* As of August 21, 2002.

743

the dates of illness onset ranged from June 10 to August 14. In addition, 1,916 dead crows and 1,567 other dead birds with WNV infection were reported from 38 states, New York City, and the District of Columbia; 256 WNV infections in mammals (all but one in horses) have been reported from 19 states (Alabama, Colorado, Florida, Georgia, Illinois, Kansas, Kentucky, Louisiana, Minnesota, Mississippi, Nebraska, New York, North Dakota, Ohio, Oklahoma, South Dakota, Tennessee, Texas, and Wyoming). During 2002, WNV seroconversions have been reported in 65 sentinel chicken flocks from Florida, Nebraska, Pennsylvania, and New York City; 1,105 WNV-positive mosquito pools have been reported from 15 states (Alabama, Georgia, Illinois, Indiana, Kentucky, Massachusetts, Mississippi, Nebraska, New Jersey, New York, Ohio, Pennsylvania, South Dakota, Texas, and Virginia), New York City, and the District of Columbia.

Additional information about WNV activity is available at http://www.cdc.gov/ncidod/dvbid/westnile/index.htm and http://www.cindi.usgs.gov/hazard/event/west_nile/ west_nile.html.

FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals ending August 17, 2002, with historical data



* No rubella cases were reported for the current 4-week period yielding a ratio for week 33 of zero (0). † Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

TABLE I. Summary of provisional cases of selected notifiable diseases, United States, cumulative, week ending August 17, 2002 (33rd Week)*

		Cum. 2002	Cum. 2001		Cum. 2002	Cum. 2001
Anthrax		2	1	Encephalitis: West Nile [†]	60	8
Botulism:	foodborne	9	16	Hansen disease (leprosy) [†]	52	46
	infant	38	58	Hantavirus pulmonary syndrome [†]	9	5
	other (wound & unspecified)	13	12	Hemolytic uremic syndrome, postdiarrheal [†]	105	84
Brucellosis [†]	,	46	83	HIV infection, pediatric ^{1§}	116	107
Chancroid		46	23	Plague	-	2
Cholera		6	3	Poliomyelitis, paralytic	-	-
Cyclosporiasis	s [†]	127	92	Psittacosis [†]	15	9
Diphtheria		1	1	Q fever [†]	23	16
Ehrlichiosis:	human granulocytic (HGE) [†]	182	130	Rabies, human	1	1
	human monocytic (HME) [†]	78	73	Streptococcal toxic-shock syndrome [†]	58	57
	other and unspecified	5	4	Tetanus	18	26
Encephalitis:	California serogroup viral [†]	25	24	Toxic-shock syndrome	75	81
	eastern equine [†]	2	4	Trichinosis	12	11
	Powassan [†]	-	-	Tularemia ⁺	40	83
	St. Louis [†]	-	27	Yellow fever	1	-
	western equine [†]	-	-			

-: No reported cases.

* Incidence data for reporting year 2001 and 2002 are provisional and cumulative (year-to-date).

[†]Not notifiable in all states.

[§] Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention (NCHSTP). Last update July 28, 2002.

MMWR

								Escheric	chia coli	
	AIC	os	Chlan	nydia†	Cryptos	poridiosis	O15	7:H7		in Positive, p non-O157
Reporting Area	Cum. 2002 [§]	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001
UNITED STATES	24,713	23,760	467,380	482,532	1,337	1,890	1,568	1,610	69	78
NEW ENGLAND	1,011	845	16,659	14,711	84	82	152	153	18	27
Maine	23	22	989	800	5	9	24	17	2	-
N.H. /t.	20 8	16 10	1,022 532	864 376	16 19	3 23	16 5	20 10	-	3 1
Aass.	519	479	6,809	6,185	23	23 36	5 69	79	5	8
R.I.	71	61	1,732	1,793	13	3	5	6	-	-
Conn.	370	257	5,575	4,693	8	8	33	21	11	15
/ID. ATLANTIC	5,619	6,282	52,438	51,880	162	185	112	117	-	-
Jpstate N.Y.	404	976	10,146	8,415	55	53	91	68	-	-
I.Y.City I.J.	3,210 925	3,338 1,070	17,942 5,696	19,329 8,303	70 8	77 9	6 15	11 38	-	-
a.	1,080	898	18,654	15,833	29	46	N	N	-	-
	2,494	1,689	78,785	88,567	342	892	365	413	8	6
Thio	2,494 453	300	19,880	22,942	342 80	892 87	305 72	413 89	8 6	о 4
nd.	347	197	9,817	9,737	27	42	34	51	-	-
l.	1,170	776	19,339	26,968	45	378	98	113	-	-
lich.	398 126	322 94	19,781	18,695	65 125	96 289	68 93	48 112	2	2
Vis.			9,968	10,225					-	
V.N. CENTRAL	421	504	25,833	24,168	159	181	249	225	8	14
1inn. owa	90 54	92 54	5,855 2,765	4,958 2,827	73 16	85 42	88 56	89 37	6	12
10.	189	233	9,245	8,828	21	26	39	31	N	N
I. Dak.	1	1	607	642	6	7	3	9	-	-
. Dak.	3	18	1,354	969	7	6	27	13	1	1
lebr.	43 41	51	1,857	2,144	26 10	15	16 20	31 15	1	1
ans.		55	4,150	3,800					-	-
ATLANTIC	7,537	7,131	89,210	93,568	200	217	145	126	21	16
)el. 1d.	131 1,066	142 899	1,628 9,477	1,811 9,465	2 13	2 28	4 12	2 9	-	-
.C.	371	507	2,054	2,043	4	9	-	-	-	-
'a.	538	593	9,894	12,070	7	15	30	34	2	2
V.Va.	58	50	1,442	1,494	2	1	2	4	-	-
I.C. S.C.	555 547	494 434	15,448 7,969	14,160 9,800	23 3	19 3	23 1	28 11	-	-
a.	1,160	852	16,899	19,765	89	92	47	22	10	- 7
la.	3,111	3,160	24,399	22,960	57	48	26	16	9	7
.S. CENTRAL	1,128	1,075	31,155	31,280	88	28	64	83	-	-
ку.	173	219	5,385	5,573	3	3	19	42	-	-
enn.	483	333	10,132	9,483	44	6	25	24	-	-
lla. Iliss.	197 275	260 263	8,867	8,546	37	10 9	14 6	11 6	-	-
			6,771	7,678	4				-	-
V.S. CENTRAL	2,696	2,406	67,576	67,830	24 7	59	25	134	-	-
urk. a.	163 693	123 548	4,088 12,050	4,751 11,277	4	5 7	5 1	5 5	-	-
Okla.	133	128	7,197	6,792	8	7	15	19	-	-
ex.	1,707	1,607	44,241	45,010	5	40	4	105	-	-
IOUNTAIN	790	843	28,777	28,252	100	85	179	151	9	9
lont.	8	13	1,338	1,288	4	7	13	8	-	-
daho	18	16	1,535	1,161	19	8	27	22	2	2
Vyo. Solo.	6 157	2 184	551 8,665	513 8,150	6 35	2 24	4 55	5 59	1 2	- 5
I. Mex.	53	75	3,990	3,854	15	15	4	9	3	2
vriz.	327	336	8,789	9,139	12	4	20	18	1	-
Itah	43	71	1,512	1,044	6	21	41	22	-	-
lev.	178	146	2,397	3,103	3	4	15	8	-	-
ACIFIC	3,017	2,985	76,947	82,276	178	161	277	208	5	6
Vash.	302 216	325 119	9,043 4,328	8,647 4,657	24 26	U 21	69 60	52 29	- 5	- 6
Dreg. Calif.	2,416	2,489	4,328 58,724	4,657 64,810	127	136	112	29 114	-	-
laska	17	14	2,155	1,711	-	1	5	3	-	-
lawaii	66	38	2,697	2,451	1	3	31	10	-	-
Guam	2	8	-	257	-	-	Ν	Ν	-	-
?R.	668	732	1,635	1,687	-	-	-	1	-	-
/.1.	66	2	98	115	-	-	-	-	-	-
Amer. Samoa	U	U	U	U	U	U	U	U	U	U

 TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending August 17, 2002, and August 18, 2001 (33rd Week)*

N: Not notifiable. U: Unavailable. -: No reported cases. C.N.M.I.: Commonwealth of Northern Mariana Islands. * Incidence data for reporting year 2001 and 2002 are provisional and cumulative (year-to-date). † Chlamydia refers to genital infections caused by *C. trachomatis.* § Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention. Last update July 28, 2002.

								<i>is influenzae</i> , asive	
	Shiga Tox	<i>ichia coli</i> kin Positive, ogrouped	Giardiasis	Gono	rrhea		Ages, rotypes	Age <5 Serot B	уре
Reporting Area	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001
UNITED STATES	30	7	9,023	197,511	221,778	1,029	994	17	17
NEW ENGLAND	-	1	954	4,649	4,055	72	68	-	1
Maine	-	-	111	78	91	1	1	-	-
N.H. Vt.	-	- 1	29 77	76 65	106 47	6 5	2 3	-	-
Mass.	-	-	465	2,053	1,888	35	36	-	1
R.I.	-	-	83	540	461	10	2	-	-
Conn.	-	-	189	1,837	1,462	15	24	-	-
MID. ATLANTIC Upstate N.Y.	-	-	1,905 648	23,984 5,107	25,595 5,212	176 76	143 47	3 2	3
N.Y. City	-	-	749	7,287	8,046	43	37	-	
N.J.	-	-	181	3,799	4,440	38	32	-	-
Pa.	-	-	327	7,791	7,897	19	27	1	3
E.N. CENTRAL	10 9	2	1,639	37,762	45,900	164 63	185 50	2	2
Ohio Ind.	9	2	507	10,796 4,289	12,540 4,127	63 33	50 36	- 1	1
III.	-	-	388	10,394	14,759	53	63	-	-
Mich. Wis.	1	-	481 263	8,678 3,605	10,791 3,683	8 7	12 24	1	-
	-	-						-	1
W.N. CENTRAL Minn.	-	2	1,041 374	10,151 1,732	10,343 1,577	42 29	47 25	1	1
lowa	-	-	160	619	824	1	-	-	-
Mo.	N	N	281	5,242	5,332	9	16	-	-
N. Dak. S. Dak.	-	2	11 45	31 160	22 146	-	4	-	-
Nebr.	-	-	74	652	763	-	1	-	1
Kans.	-	-	96	1,715	1,679	3	1	-	-
S. ATLANTIC	-	-	1,672	51,322	57,802	265	243	4	1
Del. Md.	-	-	29 67	991 5,281	1,039 5,459	- 62	62	2	-
D.C.	-	-	28	1,695	1,822	-	-	-	-
Va. W.Va.	-	-	141	5,617	7,183	22 8	19	-	-
N.C.	-	-	30	580 10,336	389 10,951	24	10 32	-	-
S.C.	-	-	50	4,804	7,214	9	4	-	-
Ga.	-	-	523 804	9,303	10,741 13,004	72 68	64 52	- 2	-
Fla.	_	-		12,715					-
E.S. CENTRAL Ky.	7 7	1	206	17,817 2,217	20,271 2,195	44 4	59 2	1	-
Tenn.	-	-	93	5,799	6,351	21	29	-	-
Ala.	-	-	113	5,709	6,669	14	26	1	-
Miss.	-	-	-	4,092	5,056	5	2	-	-
W.S. CENTRAL Ark.	-	-	122 82	29,893 2,323	33,352 2,964	40 1	39	2	1
La.	-	-	2	7,490	7,902	2	6	-	-
Okla.	-	-	38	3,059	3,119	32	32	-	-
Tex.	-	-	-	17,021	19,367	5	1	2	1
MOUNTAIN Mont.	13	1	888 57	6,085 56	6,455 78	131	104	2	4
daho	-	-	67	53	48	2	1	-	-
Wyo.	-	-	18	39	41	1	1	-	-
Colo. N. Mex.	13	1	292 97	2,111 821	1,984 601	26 19	30 16	-	- 1
Ariz.	-	-	124	2,133	2,492	63	40	1	1
Jtah	-	-	154	143	93	14	5	-	-
Nev.	-	-	79	729	1,118	6	11	1	2
PACIFIC Wash.	-	-	596 216	15,848 1,740	18,005 1,942	95 2	106 2	2 1	4
Oreg.	-	-	259	529	730	46	31	-	-
Calif.	-	-	-	12,813	14,698	19	47	1	4
Alaska Hawaii	-	-	55 66	365 401	240 395	1 27	5 21	-	-
Guam			00	101	29	_/			
P.R.	-	-	11	243	29 390	- 1	- 1	-	-
V.I.			-	25	19	-	-		
Amer. Samoa C.N.M.I.	U	U U	U	U 13	U U	U	U U	U	U U

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending August 17, 2002, and August 18, 2001

N: Not notifiable. U: Unavailable. - : No reported cases. * Incidence data for reporting year 2001 and 2002 are provisional and cumulative (year-to-date).

	Ha		<i>fluenzae</i> , Invas	ive						
	Non-So	Age < rotype B	5 Years	orotupo		<u>н</u> А	epatitis (Viral,	Acute), By Ty B	C; Non-A	Non-R
	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.
Reporting Area	2002	2001	2002	2001	2002	2001	2002	2001	2002	2001
UNITED STATES	161	164	15	22	5,266	5,854	4,227	4,450	2,919	2,603
NEW ENGLAND Maine	7	11	-	-	204 7	351 5	129 5	82 5	20	29
N.H.	-	1	-	-	11	10	12	10	-	-
Vt. Mass.	- 4	- 7	-	-	1 89	8 155	3 74	5 15	12 8	6 23
R.I.	-	-	-	-	28	16	17	15	-	- 23
Conn.	3	3	-	-	68	157	18	33	-	-
MID. ATLANTIC	23	22	-	3	618	773	856	866	1,054	802
Upstate N.Y. N.Y. City	9 7	6 6	-	1	124 253	168 269	85 451	75 403	37	18
N.J.	4	3	-	-	86	189	180	189	997	740
Pa.	3	7	-	2	155	147	140	199	20	44
E.N. CENTRAL	24	32	1	2	709	725	527	604	65	114
Ohio Ind.	7 7	9 6	1	- 1	229 33	152 57	72 31	74 31	6	7 1
III.	8	11	-	-	188	250	66	92	9	9
Mich.	1	-	-	1	154	217	358	381	50	97
Wis.	1	6	-	-	105	49	-	26	-	-
W.N. CENTRAL	2	2	3	6	226	240	134	131	579	781
Minn. Iowa	2	1	1	2	32 58	16 25	12 12	12 15	13 1	6
Mo.	-	-	2	4	62	52	75	75	553	767
N. Dak. S. Dak.	-	1	-	-	1 3	2 1	4	- 1	-	-
S. Dak. Nebr.	-	-	-	-	11	29	18	18	8	3
Kans.	-	-	-	-	59	115	13	10	4	5
S. ATLANTIC	39	34	2	5	1,639	1,115	1,122	830	112	44
Del.	-	-	-	÷	9	6	7	18	5	2
Md. D.C.	3	4	-	1	193 55	158 33	83 13	89 11	10	4
Va.	3	5	-	-	62	83	131	97	2	-
W.Va.	- 3	1	1	-	13	8 99	14	20	1	9
N.C. S.C.	2	1	-	4	151 45	99 50	163 62	131 19	18 4	13 5
Ga.	16	14	-	-	345	584	319	246	26	-
Fla.	12	8	1	-	766	94	330	199	46	11
E.S. CENTRAL	9	12	1	2	166	243	221	296	123	160
Ky. Tenn.	1 5	- 6	-	1	39 64	65 95	38 80	32 146	3 23	5 51
Ala.	3	5	1	1	25	63	47	60	4	2
Miss.	-	1	-	-	38	20	56	58	93	102
W.S. CENTRAL	9	5	-	-	191	626	332	523	822	535
Ark. La.	- 1	-	-	-	29 23	52 69	64 31	63 81	4 16	6 113
Okla.	6	5	-	-	34	91	17	71	4	4
Tex.	2	-	-	-	105	414	220	308	798	412
MOUNTAIN	27	13	7	1	394	498	395	309	67	40
Mont. Idaho	- 1	-	-	-	10 23	8 47	3 6	2 9	-	1
Wyo.	-	-	-	-	2	3	14	1	8	4
Colo.	2		-	-	67	49	56	68	28	5
N. Mex. Ariz.	4 14	7 4	1 5	1	12 210	28 256	103 149	83 97	1 4	11 9
Utah	4	2	-	-	36	55	27	15	4	2
Nev.	2	-	1	-	34	52	37	34	22	7
PACIFIC	21	33	1	3	1,119	1,283	511	809	77	98
Wash. Oreg.	1 5	1 5	-	1	112 50	87 79	39 91	81 108	15 14	16 12
Calif.	11	25	1	1	949	1,089	372	598	48	70
Alaska Hawaii	1 3	1	-	- 1	7 1	14 14	3 6	7 15	-	-
	3	I	-	I			U	10	-	-
Guam P.R.	-	- 1	-	-	- 70	1 122	- 61	- 169	-	- 1
V.I.	-	-	-	-	-	-	-	-	-	-
Amer. Samoa	U	U U	U	U	U	U U	U 25	U U	U	U U
C.N.M.I.	- Ll:Llnovailabla		-	U	-	U	35	U	-	U

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending August 17, 2002, and August 18, 2001 (33rd Week)*

N: Not notifiable. U: Unavailable. -: No reported cases. * Incidence data for reporting year 2001 and 2002 are provisional and cumulative (year-to-date).

748

Vol. 51 / No. 33	Vo	l. 51	/ No.	. 33
------------------	----	-------	-------	------

	Legion	ellosis	Lister	iosis	Lyme	Disease	Mal	aria	Meas Tot	
	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.
Reporting Area	2002	2001	2002	2001	2002	2001	2002 741	2001	2002 16 [†]	2001 94§
	547	607	285	359	6,543	9,116		914	101	
EW ENGLAND	51	34	35 2	33	1,168	2,598	43	55	-	5
laine .H.	2 4	3 6	23	2	53 128	44	3 6	3 2	-	-
t.	20	4	2	2	14	6	2	-	-	1
ass.	17	11	19	17	583	869	15	28	-	3
.I.	<u>1</u>	2	1	1	138	197	3	3	-	-
onn.	7	8	8	11	252	1,482	14	19	-	1
IID. ATLANTIC	127	140	50	61	4,366	4,901	159	257	5	18
pstate N.Y.	43	38	26	18	2,679	1,708	27	37	-	4
.Y.City .J.	23 12	23 11	11 3	15 11	81 337	56 1,675	94 20	152 40	5	6 1
a.	49	68	10	17	1,269	1,462	18	28	-	7
.N. CENTRAL	135	159	36	53	48	575	88	117	3	10
)hio	63	73	14	10	48	17	00 14	19	1	3
nd.	12	12	6	4	-0	16	6	13	2	4
l.	-	19	1	21	-	29	22	53	-	3
lich.	42	29	12	15		5	36	20	-	-
/is.	18	26	3	3	U	508	10	12	-	-
V.N. CENTRAL	28	37	8	9	143	199	46	27	1	4
linn.	2 7	9	-	-	90	150	16	6	-	2
owa	10	6 13	1 5	- 6	23 25	21 22	2 13	4 10	- 1	- 2
1o. I. Dak.	-	1	1	-	- 25	-	1	-	-	-
S. Dak.	2	3	-	-	-	-	-	-	-	-
lebr.	7	4	-	1	1	4	5	2	-	-
lans.	-	1	1	2	4	2	9	5	-	-
. ATLANTIC	104	102	50	43	681	666	218	190	1	5
Del.	6	3	-	2	83	100	2	1	-	-
/ld. D.C.	18 5	24 7	10	7	397 15	418 8	66 14	79 13	-	3
/a.	11	17	3	8	56	92	17	37	-	- 1
V.Va.	N	N	-	4	8	9	3	1	-	-
I.C.	7	7	4	2	69	26	12	9	-	-
S.C.	5	5 9	7	4 8	10	3	5	5	-	- 1
ia. Ia.	10 42	30	10 16	8	1 42	10	59 40	31 14	- 1	-
										0
E.S. CENTRAL (y.	23 9	45 11	9 2	13 4	31 13	37 17	12 5	22 8	-	2 2
enn.	8	21	4	5	11	9	2	8	-	-
la.	6	9	3	4	7	6	3	3	-	-
liss.	-	4	-	-	-	5	2	3	-	-
V.S. CENTRAL	7	17	11	28	11	65	9	64	1	1
vrk.	-	-	-	1	2	-	1	3	-	-
a. Dkla.	1 3	6 3	-	- 2	1	4	3 5	5 2	-	-
ex.	3	8	5	25	8	61	-	54	- 1	- 1
							0.4			
10UNTAIN 1ont.	25 3	33	20	28	13	7	34 1	35 2	1	1
Jaho	-	2	2	1	2	4	-	3	-	1
/yo.	1	2	-	1	-	1	-	-	-	-
olo.	4	11	3	7	3	-	19	19	-	-
l. Mex. riz.	1 7	2 8	2 9	6 6	1 2	-	2 5	3 3	-	-
tah	8	о 5	3	1	4	-	4	2	-	-
ev.	1	3	1	6	1	2	3	3	1	-
ACIFIC	47	40	66	91	82	68	132	147	4	48
lash.	5	6	5	5	6	4	12	4	-	15
reg.	N	N	8	6	12	7	7	11	-	2
alif.	42	29	47	76	63	55	105	122	3	24
laska awaii	-	1 4	- 6	- 4	1 N	2 N	2 6	1 9	-	- 7
	-	4	0	4	IN	IN	U	9	I	1
uam R.	-	-	- 1	-	- N	-	-	-	-	-
к. I.	-	2	-	-	N	N	-	3	-	-
mer. Samoa	U	U	U	U	U	U	U	U	U	U
.N.M.I.	-	Ŭ	-	Ŭ	-	Ŭ		Ŭ		Ŭ

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending August 17, 2002, and August 18, 2001

 N: Not notifiable.
 U: Unavailable.
 -: No reported cases.

 * Incidence data for reporting year 2001 and 2002 are provisional and cumulative (year-to-date).

 † Of 16 cases reported, seven were indigenous and nine were imported from another country.

 § Of 94 cases reported, 45 were indigenous and 49 were imported from another country.

	Meningo Dise		Mui	mps	Peri	tussis	Rabies	, Animal
Reporting Area	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001
UNITED STATES	1,144	1,645	174	155	4,352	3,197	3,620	4,451
NEW ENGLAND	71	76	7	1	373	289	537	441
Maine	7	1	-	-	5	-	30	45
N.H. Vt.	9 4	9 5	4	-	8 78	14 25	28 72	15 39
Mass.	33	45	2	1	266	231	174	161
R.I.	5	2	-	-	10	2	42	38
Conn.	13	14	1	-	6	17	191	143
MID. ATLANTIC Upstate N.Y.	112 34	178 49	17 2	18 3	193 139	230 111	686 420	778 488
N.Y. City	15	28	1	11	8	35	10	20
N.J.	22	30	1	-	3	8	105	122
Pa.	41	71	13	4	43	76	151	148
E.N. CENTRAL Ohio	153 57	245 66	17 2	19 1	518 261	456 199	73 16	75 23
Ind.	24	29	2	1	40	46	21	1
III.	30	59	6	14	90	45	13	11
Mich. Wis.	30 12	55 36	6 1	2 1	35 92	40 126	23	30 10
	96			7				230
W.N. CENTRAL Minn.	96 24	103 15	12 3	3	387 141	151 47	253 23	230
lowa	12	21	1	-	121	16	43	51
Mo.	37	39	3 1	-	80	66	30 11	25
N. Dak. S. Dak.	- 2	5 4	-	-	- 5	3	41	24 33
Nebr.	16	10	-	1	3	4	-	4
Kans.	5	9	4	3	37	15	105	69
S. ATLANTIC	202	258	19	22	251	154	1,537	1,540
Del. Md.	6 5	3 34	- 4	- 4	2 38	- 22	24 168	29 303
D.C.	-	-	-	-	1	1	-	-
Va.	28	31	3	5	94	26	321	273
W.Va. N.C.	3 24	11 57	- 1	- 1	23 24	2 46	118 437	92 376
S.C.	17	27	2	2	28	24	74	81
Ga.	29	36	4	7	17	17	237	260
Fla.	90	59	5	3	24	16	158	126
E.S. CENTRAL Ky.	66 11	106 19	12 4	5 1	144 57	78 19	113 18	162 16
Tenn.	26	44	2	-	54	31	59	106
Ala.	18	29	3	-	26	25	36	40
Miss.	11	14	3	4	7	3	-	
W.S. CENTRAL Ark.	137 20	250 14	14	9	1,162 389	303 12	76	797
La.	20	61	1	2	4	5	-	7
Okla.	17	23	-	-	65	12	76	48
Tex.	77	152	13	7	704	274	-	742
MOUNTAIN Mont.	70 2	74 3	13	12 1	564 4	987 20	174 10	177 26
Idaho	3	7	1	1	50	166	20	11
Wyo.	-	4	-	1	10	-	14	22
Colo. N. Mex.	22 3	29 9	2 1	3 2	217 116	207 70	29 5	- 10
Ariz.	21	11	i	1	100	461	90	104
Utah	4	7	5	1	35	52	3	3
Nev.	15	4	3	2	32	11	3	1
PACIFIC Wash.	237 46	355 51	63	62 1	760 289	549 92	171	251
Oreg.	46 34	45	N	N I	289 127	92 38	- 3	- 1
Calif.	150	248	51	29	329	387	144	212
Alaska Hawaii	1 6	2 9	- 12	1 31	4 11	3 29	24	38
Guam	0	3	-	51	-	23		
P.R.	3	4	-	-	- 1	-	49	65
V.I.	-	-	-	-	-	-	-	-
Amer. Samoa	U	U U	U	U U	U 1	U U	U	U U

 TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending August 17, 2002, and August 18, 2001

 (33rd Week)*

N: Not notifiable. -: No reported cases. * Incidence data for reporting year 2001 and 2002 are provisional and cumulative (year-to-date).

(33rd Week)*				Bul	bella			
		lountain			Cong	enital		
Departing Area	Cum. 2002	d Fever Cum. 2001	Cum. 2002	ella Cum. 2001	Cum. 2002	Cum. 2001	Salmor Cum. 2002	Cum. 2001
Reporting Area	555	331	9	16	2002	-	20,960	22,589
NEW ENGLAND	555	2	9	10	2	-	1,222	1,531
Maine	-	-	-	-	-	-	93	132
N.H.	-	-	-	-	-	-	77	121
Vt. Mass.	-	2	-	-	-	-	42 670	45 892
R.I.	-	-	-	-	-	-	95	64
Conn.	-	-	-	-	-	-	245	277
MID. ATLANTIC Upstate N.Y.	32 8	15	4 2	7 1	-	-	2,528 843	3,039 700
N.Y. City	6	1	-	5	-	-	739	780
N.J. Pa.	8 10	4 10	2	1	-	-	343 603	763 796
E.N. CENTRAL	14	14	_	2	_	_	3,222	3,163
Ohio	10	1	-	-	-	-	823	848
Ind.	2	1	-	-	-	-	290	316
III. Mich.	- 2	12	-	2	-	-	1,024 570	915 556
Wis.	-	-	-	-	-	-	515	528
W.N. CENTRAL	75	47	-	3	-	-	1,452	1,301
Minn. Iowa	- 1	2	-	- 1	-	-	340 248	388 199
Mo.	68	43	-	1	-	-	522	328
N. Dak.	-	-	-	-	-	-	25	37
S. Dak. Nebr.	- 4	2	-	-	-	-	59 70	80 99
Kans.	2	-	-	1	-	-	188	170
S. ATLANTIC	286	156	-	3	-	-	5,519	5,058
Del. Md.	2 38	1 29	-	-	-	-	40 565	57 477
D.C.	-	-	-	-	-	-	48	55
Va. W.Va.	19 1	16	-	-	-	-	562 80	858 74
N.C.	165	83	-	-	-	-	709	701
S.C.	37	16	-	2	-	-	324	488
Ga. Fla.	18 6	8 3	-	- 1	-	-	1,019 2,172	947 1,401
E.S. CENTRAL	51	67	-	-	1	-	1,495	1,324
Ky.	3	2	-	-	-	-	207	205
Tenn. Ala.	36 12	46 10	-	-	1	-	398 440	326 381
Miss.	-	9	-	-	-	-	450	412
W.S. CENTRAL	82	22	2	-	-	-	1,222	2,716
Ark.	21	4 2	-	-	-	-	500	409 473
La. Okla.	61	16	-	-	-	-	183 268	237
Tex.	-	-	2	-	-	-	271	1,597
MOUNTAIN	10	8	-	-	-	-	1,262	1,332
Mont. Idaho	1	1 1	-	-	-	-	63 85	47 89
Wyo.	3	2	-	-	-	-	38	45
Colo. N. Mex.	1	- 1	-	-	-	-	303 174	365 162
Ariz.	-	-	-	-	-	-	356	370
Utah	- 5	3	-	-	-	-	113	135
Nev.		-	-	-	-	-	130	119
PACIFIC Wash.	5	-	3	1	1	-	3,038 280	3,125 301
Oreg.	2	-	-	-	-	-	235	188
Calif. Alaska	3	-	3	-	-	-	2,305 41	2,387 27
Hawaii	-	-	-	1	- 1	-	177	222
Guam	-	-	-	-	-	-	-	18
P.R.	-	-	-	3	-	-	120	606
V.I. Amer. Samoa	- U	- U	- U	- U	- U	- U	- U	- U
C.N.M.I.	-	Ŭ	-	Ŭ	-	Ŭ	24	Ŭ

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending August 17, 2002, and August 18, 2001 (33rd Week)*

N: Not notifiable. - : No reported cases. * Incidence data for reporting year 2001 and 2002 are provisional and cumulative (year-to-date).

(33rd Week)*							-		
	Shig	jellosis	Streptococo Invasive,	cal Disease, Group A		<i>is pneumoniae,</i> tant, Invasive	Streptococcus pneumoniae, Invasive (<5 Years)		
Reporting Area	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	
UNITED STATES	9,322	11,000	2,921	2,594	1,483	1,924	157	298	
NEW ENGLAND	179	180	142	168	9	90	1	31	
Maine N.H.	3 7	6 4	20 27	10 N	-	-	N	N	
Vt.	-	6	9	9	4	7	1 N	-	
Mass. R.I.	115 7	127 8	73 13	53 8	N 5	N -	-	N 2	
Conn.	47	29	-	88	-	83	-	29	
MID. ATLANTIC Upstate N.Y.	630 145	995 349	477 223	476 204	80 72	126 122	48 48	77 77	
N.Y. City	233	271	121	135	U	U	U	U	
N.J. Pa.	148 104	202 173	91 42	91 46	N 8	N 4	N	N -	
E.N. CENTRAL	943	2,592	524	609	159	130	64	79	
Ohio Ind.	373 62	1,675 146	164 39	153 48	29 125	- 130	- 39	- 39	
III.	313	366	105	201	2	-	-	40	
Mich. Wis.	102 93	199 206	216	156 51	3 N	N	N 25	N -	
W.N. CENTRAL	699	987	180	261	152	104	36	46	
Minn. Iowa	147 75	294 301	95	112	48 N	49 N	36 N	38 N	
Mo.	109	177	37	56	6	9	-	-	
N. Dak. S. Dak.	15 150	16 92	- 10	11 7	1	5 3	-	8	
Nebr. Kans.	141 62	54 53	14 24	30 45	25 71	10 28	N N	N N	
S. ATLANTIC	3,657	1,436	584	43	915	1,031	3	4	
Del.	31	6	2	2	3	2	N	N	
Md. D.C.	685 37	79 38	95 6	N 15	N 48	N 5	N 1	N 3	
Va. W.Va.	587	172	56	62 18	N 34	N 37	N 2	N 1	
N.C.	5 216	7 240	14 102	117	34 N	37 N	U	Ŭ	
S.C. Ga.	60 1,012	175 186	28 133	8 143	138 256	212 295	N N	N N	
Fla.	1,024	533	148	77	436	480	N	N	
E.S. CENTRAL	807	956	72	79	103	190	-	-	
Ky. Tenn.	86 38	359 60	13 59	29 50	12 91	22 167	N N	N N	
Ala. Miss.	438 245	165 372	-	-	-	1	N	N	
W.S. CENTRAL	652	1,806	93	237	36	219	3	61	
Ark.	137	420	5	-	6	14	-	-	
La. Okla.	94 302	167 31	- 35	1 34	30 N	205 N	1 2	61	
Tex.	119	1,188	53	202	N	Ν	-	-	
MOUNTAIN Mont.	409 3	577 2	483	275	29	32	2	-	
Idaho	5	24	6	7	N	Ň	N	Ν	
Wyo. Colo.	5 79	2 147	7 159	7 114	9	5	-	-	
N. Mex. Ariz.	76 195	70 242	75 209	59 85	19	25	- N	- N	
Utah	23	41	209	3	- 1	-	2	-	
Nev.	23	49	-	-	-	2	-	-	
PACIFIC Wash.	1,346 96	1,471 129	366 36	47	-	2	N	N	
Oreg.	66	76	N	Ν	N	N	N	N	
Calif. Alaska	1,147 2	1,221 4	279	-	N -	N -	N N	N N	
Hawaii	35	41	51	47	-	2	-	-	
Guam P.R.	- 5	33 14	N	1 N	-	-	N	N	
V.I. Amer. Samoa	- U	- U	- U	- U	-	-	- U	- U	
C.N.M.I.	17	Ŭ	-	Ū	-	-	-	Ū	

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending August 17, 2002, and August 18, 2001 (33rd Week)*

N: Not notifiable. -: No reported cases. * Incidence data for reporting year 2001 and 2002 are provisional and cumulative (year-to-date).

(33rd Week)*		Syp	hilis			Тур	hoid		
	Primary &	Secondary		genital	Tubero	ulosis	Fever		
Reporting Area	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	
UNITED STATES	3,796	3,674	196	327	7,211	8,448	157	215	
NEW ENGLAND	82	33	-	3	238	302	11	11	
Maine N.H.	2 3	- 1	-	-	10 8	12 11	-	1 1	
Vt.	1	2	-	-	-	4	-	-	
Mass.	58	16	-	2	133	156	8	8	
R.I. Conn.	3 15	6 8	-	- 1	23 64	40 79	- 3	1	
MID. ATLANTIC	414	313	37	50	1,311	1,435	40	71	
Jpstate N.Y.	22	15	4	3	192	217	5	14	
N.Y. City N.J.	259 81	171 68	15 17	26 21	662 319	721 322	20 12	28 25	
Pa.	52	59	1	-	138	175	3	4	
E.N. CENTRAL	637	628	26	47	736	851	14	26	
Ohio Ind.	90 45	56 106	-	2 7	119 60	168 65	5 2	3 2	
III.	165	202	20	30	372	411	1	13	
Mich. Wis.	323 14	247 17	6	5 3	144 41	162 45	3 3	5 3	
W.N. CENTRAL	60	58	-	7	336	328	6	8	
Minn.	25	25	-	2	142	142	3	4	
lowa Mo.	2 15	4 11	-	- 4	17 93	18 86	- 1	- 4	
N. Dak.	-	-	-	-	1	3	-	-	
S. Dak.	- 4	- 2	-	-	9 9	8	- 2	-	
Nebr. Kans.	4 14	16	-	1	9 65	21 50	-	-	
S. ATLANTIC	1,006	1,294	44	80	1,465	1,546	27	27	
Del.	9	10	-	-	13	9	- 5	-	
Md. D.C.	122 53	169 18	8 1	3 2	168	136 47	5	8	
Va.	45	70	1	4	116	161	1	8	
W.Va. N.C.	2 182	299	16	- 8	18 199	20 202	- 1	2	
S.C.	78	170	5	18	116	124	-	-	
Ga. Fla.	198 317	230 328	1 12	18 27	250 585	276 571	8 12	6 3	
E.S. CENTRAL	331	397	13	24	432	520	4	1	
Ky.	63	29	2	-	78	78	4	-	
Tenn. Ala.	122 112	215 76	3 6	14 4	168 130	193 164	-	1	
Miss.	34	77	2	6	56	85	-	-	
W.S. CENTRAL	534	450	44	54	1,009	1,326	4	12	
Ark. La.	16 94	26 94	1	5	80	95 85	-	-	
Okla.	43	44	2	4	84	94	-	-	
Tex.	381	286	41	45	845	1,052	4	12	
MOUNTAIN Mont.	170	135	10	20	210 6	329	10	7 1	
daho	1	-	1	-	8 2	7	-	-	
Wyo. Colo.	26	- 15	- 1	- 1	2 28	2 79	5	-	
N. Mex.	21	11	-	2	21	42	-	-	
Ariz. Jtah	112 5	99 7	8	17	115 17	125 20	- 3	1	
Nev.	5	3	-	-	13	54	2	4	
PACIFIC	562	366	22	42	1,474	1,811	41	52	
Wash. Oreg.	32 11	34 8	1 1	-	155 63	164 66	4 2	3 3	
Calif.	512	315 315	19	42	1,128	1,463	34	43	
Alaska Hawaii	- 7	- 9	- 1	-	33 95	28 90	- 1	1 2	
Guam	-	9	-	- 1	-	90 45	-	2	
P.R.	139	171	10	6	33	45 53	-	-	
V.I. Amer. Samoa	1 U	- U	Ū	- U	- U	- U	- U	- U	
C.N.M.I.	14	Ŭ	-	U	29	Ŭ	-	Ŭ	

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending August 17, 2002, and August 18, 2001

N: Not notifiable. -: No reported cases. * Incidence data for reporting year 2001 and 2002 are provisional and cumulative (year-to-date).

TABLE III. Deaths in 122 U.S.	cities.* week ending August	17. 2002 (33rd Week)
	onco, noon onang ragao	

TABLE III. Deaths	in 122 0.	122 U.S. cities,* week ending August 17, 2002 (33rd Week) All Causes, By Age (Years)						ra week)	All Causes, By Age (Years)						<u> </u>
	All						P&I [†]		All						P&I [†]
Reporting Area	Ages	<u>≥</u> 65	45-64	25-44	1-24	<1	Total	Reporting Area	Ages	<u>≥</u> 65	45-64	25-44	1-24	<1	Total
NEW ENGLAND	582	408	94	55	16	9 5	53	S. ATLANTIC	1,307	812	320	115	29	29 3	106
Boston, Mass. Bridgeport, Conn.	152 29	96 20	32 4	13 5	6	5	20 4	Atlanta, Ga. Baltimore, Md.	164 267	87 156	45 78	21 22	8 6	3 5	6 31
Cambridge, Mass.	30	26	2	2	-	-	1	Charlotte, N.C.	105	69	20	10	3	3	15
Fall River, Mass.	21	12	5	4	-	-	3	Jacksonville, Fla.	91	64	18	7	2	-	12
Hartford, Conn.	54	35	12	5	1	1	4	Miami, Fla.	90	62	18	8	-	2	3
Lowell, Mass.	23	19	3	1	-	-	4	Norfolk, Va.	49	37	8	3	-	1	1
Lynn, Mass.	9	5	2	2	-	-	-	Richmond, Va.	49	24	13	6	1	5	4
New Bedford, Mass.	20	16	3	1	-	-	-	Savannah, Ga.	47	32	10	-	2	3	6
New Haven, Conn.	43	29	4	6	4	- 1	2	St. Petersburg, Fla.	61	43	17	1	- 2	- 5	8
Providence, R.I. Somerville, Mass.	47 6	35 3	8 1	2 2	1		4 1	Tampa, Fla. Washington, D.C.	170 201	113 120	29 56	20 17	2	5 2	13 7
Springfield, Mass.	50	35	8	4	2	1	4	Washington, Del.	13	5	8	-	-	-	-
Waterbury, Conn.	44	35	4	3	1	1	1					~ ~ ~		~ .	
Worcester, Mass.	54	42	6	5	1	-	5	E.S. CENTRAL	794	522	164	64	23	21	51
MID. ATLANTIC	2,006	1,366	407	151	40	42	99	Birmingham, Ala. Chattanooga, Tenn.	144 67	100 49	30 12	11 3	3 1	2	13 4
Albany, N.Y.	2,000	28	407	1	40	42	3	Knoxville, Tenn.	57	49	12	3	1	1	1
Allentown, Pa.	27	21	2	2	1	1	-	Lexington, Ky.	102	64	27	6	1	4	9
Buffalo, N.Y.	85	59	13	6	4	3	8	Memphis, Tenn.	177	108	38	14	10	7	10
Camden, N.J.	29	21	5	2	-	1	3	Mobile, Ala.	76	50	15	9	-	2	3
Elizabeth, N.J.	19	14	5	-	-	-	1	Montgomery, Ala.	37	24	6	7	-	-	2
Erie, Pa.	U	U	U	U	U	U	U	Nashville, Tenn.	134	87	24	11	7	5	9
Jersey City, N.J.	35	24	10	1	-	-	-	W.S. CENTRAL	1,229	735	272	146	50	26	67
New York City, N.Y. Newark. N.J.	1,056 45	713 14	229 16	79 10	17 2	18 3	48	Austin, Tex.	78	52	13	10	2	1	-
Paterson, N.J.	43 18	14	4	10	-	1	-	Baton Rouge, La.	43	29	10	3	-	1	-
Philadelphia, Pa.	252	162	57	21	7	5	5	Corpus Christi, Tex.	U	U	U	U	U	U	U
Pittsburgh, Pa.§	31	21	6	-	1	3	3	Dallas, Tex.	209	106	49	36	13	5	18
Reading, Pa.	28	21	4	1	1	1	2	El Paso, Tex.	80	54	17	7	2	-	2
Rochester, N.Y.	124	91	22	7	2	2	10	Ft. Worth, Tex. Houston, Tex.	94 305	42 179	22 73	19 39	9 8	2 6	5 21
Schenectady, N.Y.	21	17	2	2	-	-	4	Little Rock, Ark.	71	42	18	39 4	6	1	4
Scranton, Pa.	37	30	4	3	-	-	1	New Orleans, La.	Ű	Ű	Ŭ	Ū	Ŭ	Ů	Ū
Syracuse, N.Y.	95	71	16	6	2	-	8	San Antonio, Tex.	207	143	36	19	3	6	8
Trenton, N.J. Utica, N.Y.	29 14	16 12	3 2	8	-	2	1	Shreveport, La.	42	28	10	2	2	-	3
Yonkers, N.Y.	24	12	2	1	2	-	1	Tulsa, Okla.	100	60	24	7	5	4	6
E.N. CENTRAL	1,353	903	280	97	41	32	79		769	518	159	67	20	5	36
Akron, Ohio	49	34	11	1	1	2	6	Albuquerque, N.M. Boise, Idaho	121 34	95 23	17 8	5 1	4 1	1	3
Canton, Ohio	35	26	6	3	-	-	2	Colo. Springs, Colo.	41	28	5	6	1	1	4
Chicago, III.	U	U	U	U	U	U	U	Denver, Colo.	102	65	30	5	2	-	2
Cincinnati, Ohio	U	U	U	U	U	U	U	Las Vegas, Nev.	172	104	39	23	6	-	9
Cleveland, Ohio Columbus, Ohio	120	78	32 32	7	1	2 5	4	Ogden, Utah	38	29	1	6	2	-	2
Dayton, Ohio	179 123	121 95	15	15 9	6 3	1	13 11	Phoenix, Ariz.	U	U	U	U	U	U	U
Detroit, Mich.	100	53	24	18	3	2	4	Pueblo, Colo.	28	18	6	4	-	-	2
Evansville, Ind.	36	29	3	1	1	2	1	Salt Lake City, Utah	96	63	19	9	2	3	8
Fort Wayne, Ind.	61	39	18	3	-	1	2	Tucson, Ariz.	137	93	34	8	2	-	6
Gary, Ind.	15	7	6	1	1	-	-	PACIFIC	1,566	1,101	308	93	41	23	80
Grand Rapids, Mich.	60	39	13	1	4	3	4	Berkeley, Calif.	15	11	4	-	-	-	1
Indianapolis, Ind.	194	123	43	16	5	7	17	Fresno, Calif.	107	73	22	8	1	3	7
Lansing, Mich. Milwaukee, Wis.	U 97	U 62	U 21	U 9	U 4	U 1	U 5	Glendale, Calif. Honolulu, Hawaii	14 87	13 65	1 15	- 3	- 1	- 3	-7
Peoria, III.	32	26	3	9	4	2	1	Long Beach, Calif.	83	56	17	7	3	-	6
Rockford, III.	56	33	17	3	2	1	6	Los Angeles, Calif.	346	239	71	23	9	4	-
South Bend, Ind.	59	38	11	4	4	2	2	Pasadena, Calif.	22	16	5	1	-	-	2
Toledo, Ohio	71	47	18	5	1	-	1	Portland, Oreg.	92	67	19	3	3	-	4
Youngstown, Ohio	66	53	7	-	5	1	-	Sacramento, Calif.	161	111	26	17	2	5	6
W.N. CENTRAL	535	371	107	35	13	9	37	San Diego, Calif.	152	109	31	5	5	2	6
Des Moines, Iowa	55	37	10	7	1	-	3	San Francisco, Calif.	U 155	U 119	U 24	U 7	U 6	U	U 22
Duluth, Minn.	32	28	3	-	1	-	1	San Jose, Calif. Santa Cruz, Calif.	155 31	118 19	24 7	1	6 3	1	22 5
Kansas City, Kans.	41	27	8	3	3	-	2	Seattle, Wash.	133	89	30	9	4	1	7
Kansas City, Mo.	83	54	25	2	-	2	5	Spokane, Wash.	77	54	15	3	2	3	5
Lincoln, Nebr.	44	33	9	-	1	1	3	Tacoma, Wash.	91	61	21	6	2	1	2
Minneapolis, Minn. Omaha. Nebr.	61 74	36	14	6	2 2	3 2	4 9	TOTAL							
St. Louis, Mo.	74 U	53 U	12 U	5 U	2 U	U U	9 U	IUIAL	10,141 [¶]	6,736	2,111	823	273	196	608
St. Paul, Minn.	41	31	7	2	-	1	4								
Wichita, Kans.	104	72	19	10	3	-	6								
	No roporto				<u> </u>		~	1							

U: Unavailable. -: No reported cases.

Or Unavailable. --No reported cases.
* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.
† Pneumonia and influenza.
§ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.
† Total includes unknown ages.

755

All MMWR references are available on the Internet at http://www.cdc.gov/mmwr. Use the search function to find specific articles.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy each week, send an e-mail message to *listserv@listserv.cdc.gov*. The body content should read *SUBscribe mmwr-toc*. Electronic copy also is available from CDC's World-Wide Web server at http://www.cdc.gov/mmwr or from CDC's file transfer protocol server at ftp://ftp.cdc.gov/pub/publications/ mmwr. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone 888-232-3228.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

☆U.S. Government Printing Office: 2002-733-100/69052 Region IV